Loading…
← CockpitCompetitor Analysis › IRTC iRhythm Holdings, Inc.Open in the cockpit ↗

iRhythm Holdings, Inc.IRTCCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of wearable Zio heart-monitoring patches and AI-based analysis services diagnosing cardiac arrhythmias.

Momentum weak 23
Mkt cap
$3.19B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$107M
20-day average traded
Fwd P/E
99.8×
forward earnings
ROIC−WACC
-0.9 pp
WACC 10.8%
Hurdle
+24 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · USD$94.87
1D+5.8%
1W+7.0%
1M-16.7%
3M-25.9%
6M-18.9%
YTD-46.5%
1Y-43.4%
ATR %7.1%
Beta0.55
52w lowhigh50.7% off high

What iRhythm does

Maker of wearable Zio heart-monitoring patches and AI-based analysis services diagnosing cardiac arrhythmias.

Is paid per monitoring service, billed to Medicare and private insurers, so reimbursement rates and coverage matter as much as the devices. Patients wear the patch for about two weeks and mail it back, and the company's analysis and clinician review produce the report.

Products and services

  • Zio XT patch (long-term ECG monitoring)
  • Zio AT (real-time monitoring)
  • AI-based arrhythmia detection service

Customers

  • Cardiologists
  • Primary care physicians
  • Hospitals

Where it sits in the supply chain

  • Medical devices/diagnostics
  • Cardiac monitoring
  • Wearable ECG patch plus AI analytics…

What could go right

  • Ambulatory cardiac monitoring growth
  • International market expansion

What could go wrong

  • Reimbursement rate pressure
  • Competitive wearable monitoring market

Moat: narrow (data, brand, switching costs). Large proprietary ECG dataset trains its arrhythmia-detection algorithms, and physicians are used to its workflow.

Headquarters: San Francisco, California · Founded: 2006 · Employees: 2,400

Named competitors

iRhythm at a glance

Size iRhythm (IRTC) is a United States Health Care company (Medical Specialties) with a market value of $3.19B, the 1490th largest of 3,085 United States companies the cockpit tracks. Shares closed at $94.87 on 18 Nov 2026.

Performance Over six months the shares fell 18.9%, against +3.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 21.6% over the last twelve months (peer median +4.7%); the operating margin is 4.9% (peer median 9.9%).

Valuation It trades at 99.8× forward earnings against a peer median of 24.4× (2nd most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.9 points below its cost of capital (10.8% WACC).

Credit iRhythm has 1 bond outstanding ($661M).

Short interest Short interest is 9.7% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 104IRTC 80
Six months, rebased to 100: iRhythm against the median of its 20 peers (local-currency closes).

iRhythm financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$854M$747M$592M$493M$411M
Revenue growth—+26%+20%+20%—
Gross profit$617M$527M$408M$332M$282M
EBITDA$68.5M-$10.3M-$56.7M-$91.9M-$67.6M
Net income-$38.6M-$44.6M-$113M-$123M-$116M
Free cash flow$7.38M$34.5M-$30.6M-$90.5M-$52.8M
Capital expenditure$48.2M$46.3M$33.9M$40.4M$29.8M
Total debt$726M$731M$737M$130M$131M

Quarterly statements and history in the cockpit →

iRhythm competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%300003AFX603301688301688114TMDX603658PLSEAXGNAMBU-B4203ATRCTECN603014COTNCELC1SXPNVSTOBCK002432IRTC6-month return →1-month return →
Up and to the right = strong over both horizons. iRhythm is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×100×200×300003AFX603301688301TMDXAXGN4203ATRCTECNCOTNNVST002432IRTCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. iRhythm is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%300003AFX603301688114TMDX603658AXGNATRCTECN6030141SXP002432IRTCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. iRhythm is the large dot.

iRhythm competitors and peer comparison

Head to head with its named competitors (IRTC vs MDT vs BSX vs GEHC)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
iRhythm IRTC$3.19B-19%+22%5%99.8×46.9%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
GE HealthCare GEHC$37.8B+30%+7%14%15.6×5.0%
Koninklijke Philips PHIA.AS$29.0B+17%-1%10%16.4×5.9%

How iRhythm compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

iRhythm against its 20 peers (data as of 18 Nov 2026)
MeasureIRTCPeer medianRank in peer set
1-month return-16.7%-3.4%4th lowest of 21
6-month return-18.9%+3.2%5th lowest of 21
Distance from 52-week high-50.7%-27.7%3rd lowest of 21
Revenue growth (TTM)+21.6%+4.7%5th highest of 20
Operating margin4.9%9.9%7th lowest of 19
Forward P/E99.8×24.4×2nd most expensive of 18
Growth the price implies (Req g, 7 yrs)46.9%11.3%3rd most demanding of 17
Growth delivered (Del g)+23.0%+8.0%2nd highest of 17
Hurdle (Req g minus delivered)+23.9 pp+1.2 pp6th most demanding of 17
ROIC minus cost of capital-0.9 pp-1.2 pp8th highest of 18
EV / EBITDA48.8×16.3×2nd most expensive of 11
Net debt / EBITDA2.3×0.2×3rd most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%

iRhythm bonds and credit

iRhythm has 1 bond outstanding with $661M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are iRhythm's main competitors?
Named competitors: Medtronic (MDT), Boston Scientific (BSX), GE HealthCare (GEHC), Philips (PHIA.AS). The cockpit's measured peer set (industry) also includes Lepu Medical Technology (Beijing) (300003.SZ), Carl Zeiss Meditec (AFX.DE), Zhende Medical (603301.SS), iRay Technology (688301.SS), MGI Tech (688114.SS), TransMedics (TMDX).
Is iRhythm expensive compared with its peers?
On forward p/e it trades at 99.8× against a peer median of 24.4×, 2nd most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has iRhythm stock performed?
Over six months to 18 Nov 2026 the shares returned -18.9% against +3.2% for the median peer; over one year -43.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.